 |
|
oral JAK inhibitor INCB18424
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Oral JAK inhibitor INCB18424 specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | oral Janus-associated kinase inhibitor INCB18424 | | | | Code name: | | INCB18424 | | |
| Previous: | Optison, Ora-Testryl, Oracit, oral fludarabine phosphate, oral Hsp90 inhibitor IPI-493 | | Next: | oral JAK2 inhibitor SB1518, oral microencapsulated diindolylmethane, oral milataxel, oral picoplatin, oral sodium phenylbutyrate |
|
|
